Your browser doesn't support javascript.
Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties.
Lehman, Constance D; D'Alessandro, Helen Anne; Mendoza, Dexter P; Succi, Marc D; Kambadakone, Avinash; Lamb, Leslie R.
  • Lehman CD; Chief of Breast Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: clehman@partners.org.
  • D'Alessandro HA; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mendoza DP; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Succi MD; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kambadakone A; Chief of Abdominal Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lamb LR; Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
J Am Coll Radiol ; 18(6): 843-852, 2021 06.
Article in English | MEDLINE | ID: covidwho-1131426
ABSTRACT
Reports are rising of patients with unilateral axillary lymphadenopathy, visible on diverse imaging examinations, after recent coronavirus disease 2019 vaccination. With less than 10% of the US population fully vaccinated, we can prepare now for informed care of patients imaged after recent vaccination. The authors recommend documenting vaccination information (date[s] of vaccination[s], injection site [left or right, arm or thigh], type of vaccine) on intake forms and having this information available to the radiologist at the time of examination interpretation. These recommendations are based on three key factors the timing and location of the vaccine injection, clinical context, and imaging findings. The authors report isolated unilateral axillary lymphadenopathy (i.e., no imaging findings outside of visible lymphadenopathy), which is ipsilateral to recent (prior 6 weeks) vaccination, as benign with no further imaging indicated. Clinical management is recommended, with ultrasound if clinical concern persists 6 weeks after the final vaccination dose. In the clinical setting to stage a recent cancer diagnosis or assess response to therapy, the authors encourage prompt recommended imaging and vaccination (possibly in the thigh or contralateral arm according to the location of the known cancer). Management in this clinical context of a current cancer diagnosis is tailored to the specific case, ideally with consultation between the oncology treatment team and the radiologist. The aim of these recommendations is to (1) reduce patient anxiety, provider burden, and costs of unnecessary evaluation of enlarged nodes in the setting of recent vaccination and (2) avoid further delays in vaccinations and recommended imaging for best patient care during the pandemic.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphadenopathy / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Am Coll Radiol Journal subject: Radiology Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Lymphadenopathy / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: J Am Coll Radiol Journal subject: Radiology Year: 2021 Document Type: Article